Equity Overview
Price & Market Data
Price: $59.55
Daily Change: -$2.59 / 4.35%
Range: $59.55 - $62.14
Market Cap: $1,938,042,752
Volume: 33,278
Performance Metrics
1 Week: -0.22%
1 Month: -3.33%
3 Months: -11.71%
6 Months: -7.96%
1 Year: 22.03%
YTD: -5.63%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.